Effect of Zoledronic Acid on Acro-Osteolysis and Osteoporosis in a Patient with Hajdu-Cheney Syndrome.
10.3349/ymj.2011.52.3.543
- Author:
Sena HWANG
1
;
Dong Yoeb SHIN
;
Seong Hwan MOON
;
Eun Jig LEE
;
Sung Kil LIM
;
Ok Hwa KIM
;
Yumie RHEE
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. yumie@yuhs.ac
- Publication Type:Case Report
- Keywords:
Hajdu-Cheney Syndrome;
osteoporosis;
zoledronic acid
- MeSH:
Acro-Osteolysis/complications/*drug therapy;
Adult;
Bone Density Conservation Agents/*therapeutic use;
Diphosphonates/*therapeutic use;
Female;
Hajdu-Cheney Syndrome/complications/*drug therapy;
Humans;
Imidazoles/*therapeutic use;
Osteoporosis/complications/*drug therapy
- From:Yonsei Medical Journal
2011;52(3):543-546
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hajdu-Cheney syndrome is a rare, autosomal dominant skeletal dysplasia marked by acro-osteolysis of the distal phalanges and severe osteoporosis. Although there are more than 60 reports published to date, proper treatment and subsequent outcome have been scarce. Herein, we report a progress of anti-resorptive therapy with zoledronic acid, in a woman with Hajdu-Cheney syndrome. Results suggest that anti-resorptive therapy may be important in delaying the progress of osteoporosis and preventing fractures, but not necessarily acro-osteolysis itself.
